The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2016
Filed:
Feb. 24, 2015
Applicant:
Abbvie Biotechnology Ltd, Hamilton, BM;
Inventors:
Zehra Kaymakcalan, Westborough, MA (US);
Limin Xiong, Shrewsbury, MA (US);
Assignee:
ABBVIE BIOTECHNOLOGY LTD., Hamilton, BM;
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/42 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C12N 5/20 (2006.01); G01N 33/536 (2006.01); G01N 33/543 (2006.01); G01N 33/58 (2006.01); G01N 33/60 (2006.01); G01N 33/68 (2006.01); C12N 5/16 (2006.01); G01N 33/94 (2006.01);
U.S. Cl.
CPC ...
C07K 16/4241 (2013.01); A61K 39/39566 (2013.01); A61K 45/06 (2013.01); C12N 5/163 (2013.01); G01N 33/536 (2013.01); G01N 33/543 (2013.01); G01N 33/581 (2013.01); G01N 33/60 (2013.01); G01N 33/686 (2013.01); G01N 33/6857 (2013.01); G01N 33/9493 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); Y10S 435/975 (2013.01); Y10S 530/866 (2013.01);
Abstract
Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.